Stock Market Reviews

DNTH (Dianthus Therapeutics, Inc.) News

Get the latest news, insights, and market updates on DNTH (Dianthus Therapeutics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Dianthus Enters License Agreement for Autoimmune Drug; Shares Rise
  Dianthus Therapeutics (DNTH) said Thursday it has entered into a licensing agreement with Nanjing Le
  Oct 16, 2025 - $DNTH
• Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
  Positive results from Phase 2 MaGic trial including additional analyses, and new preclinical data highlighting potential benefits of upstream inhibition, to be presented for claseprubart in generalized Myasthenia GravisNEW YORK and WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced tha
  Oct 2, 2025 - $DNTH
• Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target
  Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best fast money stocks to buy now. Clear Street assumed coverage on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) with a ‘Buy’ rating and a price target of $100, implying a potential upside of nearly 172% from the current price. This optimism is driven by the company’s lead candidate, Claseprubart, which […]
  Sep 30, 2025 - $DNTH
• Dianthus, Opendoor, and More Stocks See Action From Activist Investors
  13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
  Sep 19, 2025 - $DNTH
• Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise
  Dianthus Therapeutics, Inc. recently announced positive topline data from its Phase 2 MaGic trial, showing that claseprubart achieved statistically significant and clinically meaningful improvements in adults with generalized Myasthenia Gravis, and followed this with an upsized public equity offering raising approximately US$251 million through common stock and pre-funded warrants. An important insight is that claseprubart's favorable safety profile and efficacy support biweekly...
  Sep 13, 2025 - $DNTH
• Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
  NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases (“Dianthus” or the “Company”), today announced that it closed its previously announced underwritten public offering of 7,627,879 shares of its common stock, including the full exercise by the underwriters of their option to purchase an ad
  Sep 11, 2025 - $DNTH
• Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
  NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases (“Dianthus” or the “Company”), today announced the pricing of its previously announced upsized underwritten public offering of 6,487,879 shares of its common stock at a public offering price per share of $33.00 and, in lieu of common stoc
  Sep 10, 2025 - $DNTH
• Dianthus to take gMG mAb to Phase III after mid-stage win
  Despite strong competition in the gMG space, analysts have high hopes for claseprubart if it were to be approved.
  Sep 9, 2025 - $DNTH
• Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential
  We recently published 10 Stocks With Eye-Popping Gains; 7 Soar to Fresh Highs. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is one of the top performers on Monday. Dianthus Therapeutics soared to a new record high on Monday, as investors cheered impressive results from its clinical trial of a potential treatment for generalized Myasthenia Gravis (gMG), a rare […]
  Sep 9, 2025 - $DNTH
• Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
  Shares of Dianthus Therapeutics surged Monday after the company's autoimmune disease treatment succeeded in a midstage study.
  Sep 8, 2025 - $DNTH